Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Símbolo de cotizaciónFLGT
Nombre de la empresaFulgent Genetics Inc
Fecha de salida a bolsaSep 28, 2016
Director ejecutivoMr. Ming Hsieh
Número de empleados1313
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 28
Dirección4399 Santa Anita Ave
CiudadEL MONTE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal91731
Teléfono16263500537
Sitio Webhttps://www.fulgentgenetics.com/
Símbolo de cotizaciónFLGT
Fecha de salida a bolsaSep 28, 2016
Director ejecutivoMr. Ming Hsieh
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos